glp-1 receptor agonists adverse effects Your guide to side Clinical Recommendations to Manage Gastrointestinal
Description
Among adolescents aged 1217 years with obesity, prescription use increased from 0.1 percent in 2020 to 0.5 percent in 2023, representing a relative rise of more than 300 percent, although total usage remains below 1 percent
However, for people with significant metabolic dysfunction like type 2 diabetes, the enhanced metabolic benefits might matter
doi: 10.1681/ASN.2014010085
Researchers noted that people receiving the medication experienced statistically significant and clinically meaningful weight loss starting at 28 weeks
(7) Oral formulation
